EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group (Q36080426)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

author name string

P H De Mulder

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

G Oosterhof

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

C Bouffioux

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

A T van Oosterom

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

K Vermeylen

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

R Sylvester

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

language of work or name

0 references

publication date

1 February 1995

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

71

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

371-375

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Interferon treatment of renal cell carcinoma. Current status and future prospects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033601

2 October 2017

Hormonal therapy and chemotherapy of renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033601

2 October 2017

Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human alpha, beta, and gamma interferons

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033601

2 October 2017

Immunologic therapies of kidney carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033601

2 October 2017

Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033601

2 October 2017

Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033601

2 October 2017

Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033601

2 October 2017

Interferon therapy of metastatic renal cell cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033601

2 October 2017

Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033601

2 October 2017

An assessment of the current use of human interferons in therapy of urological cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033601

2 October 2017

Therapeutic options in renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033601

2 October 2017

Interferon therapy in cancer: from imaginon to interferon.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033601

2 October 2017

Phase II study of recombinant human interferon-gamma in metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033601

2 October 2017

Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033601

2 October 2017

The Role of Adjunctive Nephrectomy in Patients with Metastatic Renal Cell Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033601

2 October 2017

Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033601

27 July 2018

Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Reduced toxicity without reduction of the response rate--a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033601

27 July 2018

Interferon in renal cell carcinoma. The UCLA experience.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033601

23 September 2018

Interferon-induced enhancement of 2',5'-oligoadenylate synthetase in mid-gut carcinoid tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/7841054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The natural history of renal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/7841054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/7841054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synergistic antiproliferative effect of recombinant alpha-interferons with recombinant gamma-interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/7841054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/7841054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The determination of an immunologically active dose of interferon-gamma in patients with melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/7841054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/7841054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alpha and gamma interferon in the treatment of advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/7841054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant interferon gamma in the treatment of metastatic renal cell carcinoma. Results of a phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/7841054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective randomized trial of alpha 2B-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/7841054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II study of recombinant interferon alpha and gamma in advanced progressive renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/7841054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/7841054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1995.75

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36080426&oldid=2198169737"